The 11 most recent market catalysts affecting $HALO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Halozyme Therapeutics Prices Upsized $1.3B Offering Of 1.50% Convertible Senior Notes Due 2033
This headline signifies a significant financing event for Halozyme Therapeutics. The upsized offering of convertible senior notes provides a substantial capital injection, which ca…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
Halozyme Therapeutics Announces Proposed $1.05B Convertible Senior Notes Offering Due 2033
Halozyme Therapeutics is seeking to raise $1.05 billion through the issuance of convertible senior notes, with an option for an additional $150 million. This financing strategy all…
Aug 25, 2026
Market Technicals
Neutral
Impact 55
Watching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Sells Stock
This headline primarily reflects a technical signal rather than a fundamental change in Halozyme Therapeutics' business. The 'Investor Business Daily SwingTrader' is a recognized e…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 55
Watching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Buys Stock
The headline indicates that Investor's Business Daily's SwingTrader, a publication known for technical analysis and short-term trading signals, has bought stock in Halozyme Therape…
Aug 8, 2026
Corporate Catalyst
Bullish
Impact 65
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110
Leerink Partners' upgrade of Halozyme Therapeutics from Market Perform to Outperform, coupled with a significant price target increase from $83 to $110, indicates a more bullish ou…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 60
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105
TD Cowen analyst Brendan Smith has maintained a 'Buy' rating on Halozyme Therapeutics and raised the price target from $96 to $105. This upgrade in price target indicates increased…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 85
Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates. HC Wainwright & Co raised its price target on the stock from $95 to $115.
This headline indicates a strong positive catalyst for Halozyme Therapeutics. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26) suggest fundamen…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Halozyme Therapeutics and raised the price target from $95 to $115. This action signals increased co…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 95
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate
Halozyme Therapeutics reported Q2 adjusted EPS of $2.28, significantly beating the $1.84 estimate by 23.91%, and sales of $480.999 million, surpassing the $407.493 million estimate…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a 'Buy' rating and a $95 price target for Halozyme Therapeutics. This action signals that the analyst's investment the…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody
Halozyme Therapeutics announced a collaboration with Incyte to improve the subcutaneous delivery of Incyte's INCA033989, a promising cancer drug. This is a positive development for…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.